ALLO Allogene Therapeutics, Inc.: institutional ownership and insider trading
223 funds reported holding $670M of Allogene Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net bought $268M, with 32 new positions and 29 funds selling out; over the last 12 months insiders bought $0 and sold $669K on the open market.
ALLO revenue and earnings
- Quarter ended Jun 30, 2026: revenue $4.64M, net income −$42.7M, EPS -0.13
- Quarter ended Mar 31, 2026: revenue n/a, net income −$42.6M, EPS -0.18
- Quarter ended Dec 31, 2025: revenue $0, net income −$38.8M, EPS -0.17
- Quarter ended Sep 30, 2025: revenue $0, net income −$41.4M, EPS -0.19
Famous investors holding ALLO
- Two Sigma (Two Sigma Investments): $16.2M, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $7.98M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $21.3M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $10.1M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $9.80M, 0.0% of the portfolio
Largest institutional holders of ALLO
- BlackRock, Inc. (BLK) — $62.7M
- PFIZER INC (PFE) — $46.9M
- Frazier Life Sciences Management, L.P. — $46.7M
- STATE STREET CORP (STT, STT-PG) — $39.6M
- TPG GP A, LLC — $38.9M
- Sio Capital Management, LLC — $27.7M
- PRIMECAP MANAGEMENT CO/CA/ — $27.3M
- VANGUARD CAPITAL MANAGEMENT LLC — $25.3M
- FMR LLC — $25.0M
- CITADEL ADVISORS LLC — $21.3M
Recent ALLO insider trades
- Oct 21, 2026: Parker Geoffrey M. sold 36,342 shares ($48.7K)
- Aug 21, 2026: Douglas Earl Martin sold 29,697 shares ($63.0K)
- Apr 21, 2026: Yoshiyama Annie sold 9,586 shares ($22.1K)
- Mar 31, 2026: Beneski Benjamin Machinas sold 2,867 shares ($7.17K)
5%+ owners
- Frazier Life Sciences Public Fund, L.P.: 5.6% (Schedule 13G/A, filed Aug 14, 2026)
- STATE STREET CORPORATION: 5.5% (Schedule 13G, filed Aug 7, 2026)